Ovarian Cancer Clinical Trial

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Summary

This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

View Full Description

Full Description

While ABCB1 (P-glycoprotein 1) upregulation after paclitaxel administration is well known, there is currently no clinically available method for preventing or overcoming it. To develop a therapy able to prevent ABCB1 upregulation and paclitaxel resistance, several ABCB1 inhibitors have been evaluated in combination with paclitaxel in preclinical model systems. Pulsed-dose lapatinib and paclitaxel are synergistic and inhibition of ABCB1 by lapatinib increases sensitivity to paclitaxel. Lapatinib is FDA approved, orally available, and previously studied in combination with weekly paclitaxel for breast cancer at doses of 1000mg to 1250mg daily (7000-8250mg per week). This trial will use twice-daily dosing of lapatinib at a starting dose of 750 mg for 2 days (1500mg a day and 3000mg weekly dose), which is less than half of the continuous dose and has been shown to achieve plasma concentrations at 48 hours that are associated with synergy. Therefore, these findings can be translated into a novel, well-tolerated, and convenient combination regimen with significant potential for clinical activity. This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

histologically or cytologically confirmed ovarian cancer who recur within 12 months of platinum-based chemotherapy
ECOG performance status less than or equal to 2
Adequate organ and marrow function at baseline
ability to sign a written informed consent document

Exclusion Criteria:

hypersensitivity to lapatinib or paclitaxel
uncontrolled intercurrent illness
receiving medications that inhibit or induce CYP3A4
malabsorption syndrome
congestive heart failure
receiving any other anti-cancer investigational agents
baseline neuropathy greater than Grade 1

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

15

Study ID:

NCT04608409

Recruitment Status:

Recruiting

Sponsor:

Frederick R. Ueland, M.D.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Markey Cancer Center
Lexington Kentucky, 40536, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

15

Study ID:

NCT04608409

Recruitment Status:

Recruiting

Sponsor:


Frederick R. Ueland, M.D.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.